Current methods for treating diabetic retinopathy (DR), including laser photocoagulation and anti-vascular endothelial growth factor (VEGF), are limited by significant side effects and do not eliminate the risk of blindness. The gene discussed is VEGFA; the disease is blindness (disorder).